Associated Papers
Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy.
Duineveld C et al.
Transplantation, 2025
39049128 (PubMed )
Supplement: tpa-109-511-s001.pdf
C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients.
Guaschino V et al.
Frontiers in Immunology, 2025
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study.
Brocklebank V et al.
Blood, 2023
37369098 (PubMed )
Supplement: BLOOD_BLD-2022-018833R2-mmc1.pdf
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.
Acosta-Medina AA et al.
Blood Advances, 2023
35533258 (PubMed )
Supplement: BLOODA_ADV-2021-006416-mmc1.pdf
An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome.
Gastoldi S et al.
Frontiers in Immunology, 2023
C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19.
Aiello S et al.
Blood Advances, 2022
Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality.
Ardissino G et al.
Kidney International Reports, 2021
34169201 (PubMed )
Supplement: mmc1.pdf
Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration.
Geerlings MJ et al.
Clinical Genetics, 2018
29888403 (PubMed )
Supplement: CGE-94-330-s001.zip › Appendix_S1 › Table_S3.xlsx › C3
Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome.
Gleeson PJ et al.
Immunobiology, 2016
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode.
Forneris F et al.
The Embo Journal, 2016
Comprehensive Analysis of Complement Genes in Patients with Atypical Hemolytic Uremic Syndrome.
Zhang T et al.
American Journal of Nephrology, 2016
Select a paper to view details